Abstract
Nanoparticles have emerged as a powerful tool in the field of cancer therapy, offering the potential to improve drug delivery, reduce systemic toxicity, and enhance therapeutic efficacy. Their unique physicochemical properties allow for the development of targeted therapies that exploit tumor-specific characteristics. However, several challenges hinder the widespread clinical application of nanoparticle-based cancer treatments. This article explores the opportunities presented by nanoparticle platforms, the biological and regulatory hurdles they face, and the ongoing research efforts to overcome these barriers.
All articles published in the American Journal of Pharmacy and Pharmacology are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows others to:
-
Share — copy and redistribute the material in any medium or format
-
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Under the following terms:
-
Attribution — Appropriate credit must be given to the original author(s) and source, a link to the license must be provided, and any changes made must be indicated.
By submitting their work, authors agree to these licensing terms and retain copyright of their articles.